Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Open accessThe DOI matches its Crossref record; 273 of the 276 references it cites were found in a registry or an index.
Abstract
We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinopathy in older adults, with or without coexisting hippocampal sclerosis pathology. LATE-NC is a common TDP-43 proteinopathy, associated with an amnestic dementia syndrome that mimicked Alzheimer's-type dementia in retrospective autopsy studies. LATE is distinguished from frontotemporal lobar degeneration with TDP-43 pathology based on its epidemiology (LATE generally affects older subjects), and relatively restricted neuroanatomical distribution of TDP-43 proteinopathy. In community-based autopsy cohorts, ∼25% of brains had sufficient burden of LATE-NC to be associated with discernible cognitive impairment. Many subjects with LATE-NC have comorbid brain pathologies, often including amyloid-β plaques and tauopathy. Given that the 'oldest-old' are at greatest risk for LATE-NC, and subjects of advanced age constitute a rapidly growing demographic group in many countries, LATE has an expanding but under-recognized impact on public health. For these reasons, a working group was convened to develop diagnostic criteria for LATE, aiming both to stimulate research and to promote awareness of this pathway to dementia. We report consensus-based recommendations including guidelines for diagnosis and staging of LATE-NC. For routine autopsy workup of LATE-NC, an anatomically-based preliminary staging scheme is proposed with TDP-43 immunohistochemistry on tissue from three brain areas, reflecting a hierarchical pattern of brain involvement: amygdala, hippocampus, and middle frontal gyrus. LATE-NC appears to affect the medial temporal lobe structures preferentially, but other areas also are impacted. Neuroimaging studies demonstrated that subjects with LATE-NC also had atrophy in the medial temporal lobes, frontal cortex, and other brain regions. Genetic studies have thus far indicated five genes with risk alleles for LATE-NC: GRN, TMEM106B, ABCC9, KCNMB2, and APOE. The discovery of these genetic risk variants indicate that LATE shares pathogenetic mechanisms with both frontotemporal lobar degeneration and Alzheimer's disease, but also suggests disease-specific underlying mechanisms. Large gaps remain in our understanding of LATE. For advances in prevention, diagnosis, and treatment, there is an urgent need for research focused on LATE, including in vitro and animal models. An obstacle to clinical progress is lack of diagnostic tools, such as biofluid or neuroimaging biomarkers, for ante-mortem detection of LATE. Development of a disease biomarker would augment observational studies seeking to further define the risk factors, natural history, and clinical features of LATE, as well as eventual subject recruitment for targeted therapies in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Statistical analyses on data related to LATE from the Rush University community-based autopsy cohort depicting the results of pathway analyses. Data were analysed from research volunteers (total n = 1309) in two clinical‐pathological studies of ageing from Rush University as described previously (Power et al., 2018). In this sample, the mean age of death was 89.7 years [standard deviation (SD) 6.5 years, range 65–108 years]. These analyses incorporated age, density of amyloid-β neuritic amyloid plaques (to factor in ADNC), TDP-43 proteinopathy, hippocampal sclerosis pathology, and the endpoint of Alzheimer’s-type clinical dementia. The components of the pathway analyses most strongly associated with LATE-NC are shown in red. The numbers are path coefficients with standard error in parentheses (shown in purple). These numbers help to quantify the effects of individual pathways. For instance, the data are compatible with there being two pathways from TDP-43 proteinopathy to dementia, one direct pathway (TDP-43 proteinopathy→dementia) and the other indirect pathway that includes hippocampal sclerosis pathology (TDP-43 proteinopathy→hippocampal sclerosis→dementia): in the statistical model, the TDP-43 proteinopathy is independently associated with both hippocampal sclerosis pathology and clinical dementia status. Further, the data indicate that a subset of TDP-43 proteinopathy is ‘downstream’ of ADNC-type neuritic amyloid plaque pathology. In a practical sense, this means that brains with more neuritic amyloid plaques are more likely to have TDP-43 proteinopathy, with all other known factors being the same. Aβ = amyloid-β.](https://figures.cochat.ai/paper-figures/9bc83b3adf7f42d5a250b59d9652e7a1/limbic-predominant-age-related-tdp-43-encephalopathy-late-consensus-working-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A consensus group, for example, has described hippocampal sclerosis associated with TDP-43 proteinopathy, as limbic-predominant age-related TDP-43 encephalopathy (LATE) dementia, usually found in people older than 80 years, progressing more slowly than Alzheimer's disease, detectable at post-mortem, often mimicking or comorbid with Alzheimer's disease.3”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“50–60% of Alzheimer’s-type dementia (dementia defined clinically as Alzheimer’s disease) is estimated to be attributable to these copathologies.40,42–45”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LATE is a recently described entity which affects older people and presents with an amnestic picture resembling Alzheimer's disease 178 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [178]
The cited source says what the claim attributes to it.
In the citing paper
“Limbic-predominant age-related TDP43 encephalopathy (LATE), defined approximately 3 years ago, is a condition in which typical TDP43 protein inclusions are present with or without coexisting hippocampal sclerosis.29”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The predominant neuropathological change in LATE is TDP-43 proteinopathy, which is associated with a clinical presentation of amnestic dementia that can mimic Alzheimer's dementia.”
From Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy (2020) · cites this paper as [20]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576
Self-citationBlessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · cited 1×
“LATE-NC is mostly seen in the oldest-old, whereas in early clinical-pathological correlation studies of dementia (Roth et al., 1966; Blessed et al., 1968), the research subjects had died in their early 70s.”
BackgroundAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This stratification will enable enrichment for subjects on the ADNC continuum (Sevigny et al., 2016) while excluding subjects likely to have high risk for LATE-NC (Botha et al., 2018).”
BackgroundMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Self-citationStages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“seen at autopsy with every year of advanced old age (Braak et al., 2011; Nelson et al., 2011a, 2013; Brenowitz et al., 2014; Neltner et al., 2016).”
BackgroundPorta, M. (2026) · doi:10.1093/acref/9780197663639.001.0001 · Cited by 2,175
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citation
Research works printed but not linked: 3
- Kuslansky G, Verghese J, Dickson D, Katz M, Busche H, Lipton RB Hippocampal sclerosis: cognitive consequences and contribution to dementia. Neurology 2004; 62: A128– 9.
- Porta M. Dictionary of Epidemiology. 6th edn. New York: Oxford University Press; 2014.
- Thom M, Sisodiya S Epilepsy. In: Love S, Perry A, Ironside JW, Budka H, editors. Greenfield’s Neuropathology. New York: CRC Press; 2015 p. 683– 739.
Cited by
Items 201–300 of 1,004
Nicks, R., Clement, N. F., Alvarez, V. E., Tripodis, Y., Baucom, Z. H., Huber, B. R., Mez, J., Alosco, M. L., Aytan, N., Cherry, J. D., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02539-3 · Cited by 58
Ergothioneine promotes longevity and healthy aging in male mice
Katsube, M., Ishimoto, T., Fukushima, Y., Kagami, A., Shuto, T., & Kato, Y. (2024) · GeroScience · doi:10.1007/s11357-024-01111-5 · Cited by 58
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
Ossenkoppele, R., Leuzy, A., Cho, H., Sudre, C. H., Strandberg, O., Smith, R., Palmqvist, S., Mattsson-Carlgren, N., Olsson, T., Jögi, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05099-w · Cited by 50
Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD
Tamaki, Y., & Urushitani, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012508 · Cited by 57
Spence, H., Waldron, F. M., Saleeb, R. S., Brown, A., Rifai, O. M., Gilodi, M., Read, F. L., Roberts, K., Milne, G., Wilkinson, D., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02705-1 · Cited by 57
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 57
The Dynamics of Dementia Communication
Wray, A. (2020) · doi:10.1093/oso/9780190917807.001.0001 · Cited by 57
A role of the frontotemporal lobar degeneration risk factor TMEM106B in myelination
Feng, T., Sheng, R. R., Solé-Domènech, S., Ullah, M., Zhou, X., Mendoza, C. S., Enriquez, L. C. M., Katz, I. I., Paushter, D. H., Sullivan, P. M., et al. (2020) · Brain · doi:10.1093/brain/awaa154 · Cited by 53
Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease
Teipel, S. J., Fritz, H.-C., Grothe, M. J., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010192 · Cited by 57
Molecular Imaging Approaches in Dementia
Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A., & van Berckel, B. N. M. (2021) · Radiology · doi:10.1148/radiol.2020200028 · Cited by 50
Liquid–Liquid Phase Separation Enhances TDP-43 LCD Aggregation but Delays Seeded Aggregation
Pakravan, D., Michiels, E., Bratek‐Skicki, A., Decker, M. D., Lindt, J. V., Alsteens, D., Derclaye, S., Damme, P. V., Schymkowitz, J. W. H., Rousseau, F., et al. (2021) · Biomolecules · doi:10.3390/biom11040548 · Cited by 57
Ni, J., Ren, Y., Su, T., Zhou, J., Fu, C., Lu, Y., Li, D., Zhao, J., Li, Y., Zhang, Y., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01346-0 · Cited by 57
White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition
Raghavan, S., Przybelski, S. A., Reid, R. I., Lesnick, T. G., Ramanan, V. K., Botha, H., Matchett, B. J., Murray, M. E., Reichard, R. R., Knopman, D. S., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01319-6 · Cited by 49
Self-citationNelson, P. T., Fardo, D. W., Wu, X., Aung, K. Z., Cykowski, M. D., & Katsumata, Y. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae032 · Cited by 56
Self-citationMultimorbidity in dementia: Current perspectives and future challenges
Stirland, L., Choate, R., Zanwar, P., Zhang, P., Watermeyer, T., Valletta, M., Torso, M., Tamburin, S., Saeed, U., Ridgway, G. R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70546 · Cited by 56
Agrawal, S., Yu, L., Kapasi, A., James, B. D., Arfanakis, K., Barnes, L. L., Bennett, D. A., Nag, S., & Schneider, J. A. (2021) · Brain Pathology · doi:10.1111/bpa.12939 · Cited by 56
Self-citationMitigation of ALS Pathology by Neuron-Specific Inhibition of Nuclear Factor Kappa B Signaling
Dutta, K., Thammisetty, S. S., Boutej, H., Bareil, C., & Julien, J.-P. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0536-20.2020 · Cited by 55
Association of small vessel disease with tau pathology
Kapasi, A., Yu, L., Petyuk, V., Arfanakis, K., Bennett, D. A., & Schneider, J. A. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02397-x · Cited by 55
Self-citationTDP-43 Oligomerization and Phase Separation Properties Are Necessary for Autoregulation
Koehler, L. C., Grese, Z. R., Bastos, A. C. S., Mamede, L. D., Heyduk, T., & Ayala, Y. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.818655 · Cited by 55
Ahmad, A., Uversky, V., & Khan, R. H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.08.132 · Cited by 42
TDP-43 Proteinopathy Specific Biomarker Development
Cordts, I., Wachinger, A., Scialò, C., Lingor, P., Polymenidou, M., Buratti, E., & Feneberg, E. (2023) · Cells · doi:10.3390/cells12040597 · Cited by 55
Thomas, D. X., Bajaj, S., McRae-McKee, K., Hadjichrysanthou, C., Anderson, R. M., & Collinge, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-71305-2 · Cited by 51
Abnormal tau in amyloid PET negative individuals
Yoon, B., Guo, T., Provost, K., Korman, D., Ward, T. J., Landau, S. M., & Jagust, W. J. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.09.019 · Cited by 55
Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”
Outeiro, T. F., Alcalay, R. N., Antonini, A., Attems, J., Bonifati, V., Cardoso, F., Chesselet, M., Hardy, J., Madeo, G., McKeith, I. G., et al. (2023) · Movement Disorders · doi:10.1002/mds.29419 · Cited by 54
Self-citationAsken, B. M., Tanner, J. A., VandeVrede, L. A., Casaletto, K. B., Staffaroni, A. M., Mundada, N. S., Fonseca, C. S., Iaccarino, L., Joie, R. L., Tsuei, T., et al. (2022) · Journal of Neurotrauma · doi:10.1089/neu.2022.0060 · Cited by 54
Self-citationMontine, T. J., Corrada, M. M., Kawas, C., Bukhari, S. A., White, L. R., Tian, L., & Cholerton, B. (2022) · Neurology · doi:10.1212/wnl.0000000000200832 · Cited by 47
Self-citationKhalil, B., Chhangani, D., Wren, M. C., Smith, C. L., Lee, J. H., Li, X., Puttinger, C., Tsai, C.-W., Fortin, G., Morderer, D., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00585-1 · Cited by 54
Self-citationHsp90 and its co‐chaperone Sti1 control TDP‐43 misfolding and toxicity
Lin, L. T., Razzaq, A., Gregorio, S. E. D., Hong, S., Charles, B., Lopes, M. H., Beraldo, F. H., Prado, V. F., Prado, M. A. M., & Duennwald, M. L. (2021) · The FASEB Journal · doi:10.1096/fj.202002645r · Cited by 53
Walker, L., & Attems, J. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230154 · Cited by 55
Self-citationNeuroimaging of Alzheimer’s disease: focus on amyloid and tau PET
Matsuda, H., Shigemoto, Y., & Sato, N. (2019) · Japanese Journal of Radiology · doi:10.1007/s11604-019-00867-7 · Cited by 52
Alzheimer’s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α
Sáez-Orellana, F., Octave, J., & Pierrot, N. (2020) · Cells · doi:10.3390/cells9051215 · Cited by 52
From beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 53
Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy
Katsumata, Y., Abner, E. L., Karanth, S. D., Teylan, M., Mock, C., Cykowski, M. D., Lee, E. B., Boehme, K. L., Mukherjee, S., Kauwe, J. S. K., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02211-0 · Cited by 52
Self-citationRojas‐Prats, E., Martínez‐González, L., Gonzalo‐Consuegra, C., Liachko, N. F., Perez, C., Ramírez, D., Kraemer, B. C., Martín‐Requero, Á., Pérez, D. I., Gil, C., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112968 · Cited by 52
Agrawal, S., Yu, L., Nag, S., Arfanakis, K., Barnes, L. L., Bennett, D. A., & Schneider, J. A. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01260-0 · Cited by 52
Self-citationScheppach, J. B., Wu, A., Gottesman, R. F., Mosley, T. H., Arsiwala-Scheppach, L. T., Knopman, D. S., Grams, M. E., Sharrett, A. R., Coresh, J., & Koton, S. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.07.013 · Cited by 53
Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome
Corriveau‐Lecavalier, N., Botha, H., Graff‐Radford, J., Switzer, A. R., Przybelski, S. A., Wiste, H. J., Murray, M. E., Reichard, R. R., Dickson, D. W., Nguyen, A. T., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae183 · Cited by 52
Self-citationCreation of de novo cryptic splicing for ALS and FTD precision medicine
Wilkins, O. G., Chien, M. Z. Y. J., Wlaschin, J. J., Barattucci, S., Harley, P., Mattedi, F., Mehta, P. R., Pisliakova, M., Ryadnov, E. M., Keuss, M. J., et al. (2024) · Science · doi:10.1126/science.adk2539 · Cited by 51
Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology
Scarioni, M., Gami‐Patel, P., Timar, Y. S. S., Seelaar, H., Swieten, J. C. V., Rozemüller, A. J. M., Dols, A., Scarpini, E. A., Galimberti, D., Bank, N. B., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25739 · Cited by 51
Breakdown of specific functional brain networks in clinical variants of Alzheimer’s disease
Pini, L., Wennberg, A. M. V., Salvalaggio, A., Vallesi, A., Pievani, M., & Corbetta, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101482 · Cited by 51
Long, J. M., Coble, D. W., Xiong, C., Schindler, S. E., Perrin, R. J., Gordon, B. A., Benzinger, T. L. S., Grant, E., Fagan, A. M., Harari, O., et al. (2022) · Brain · doi:10.1093/brain/awac250 · Cited by 52
Gauthreaux, K. M., Teylan, M., Katsumata, Y., Mock, C., Culhane, J. E., Chen, Y., Chan, K. C. G., Fardo, D. W., Dugan, A. J., Cykowski, M. D., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200001 · Cited by 50
Self-citationNeuropathology of the Common Forms of Dementia
Mehta, R. I., & Schneider, J. A. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.07.005 · Cited by 50
Self-citationMagnetic resonance imaging brain atrophy assessment in primary age-related tauopathy (PART)
Quintas-Neves, M., Teylan, M., Besser, L. M., Soares-Fernandes, J. P., Mock, C., Kukull, W. A., Crary, J. F., & Oliveira, T. G. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0842-z · Cited by 50
Self-citationPérez, E., Justo‐Henriques, S. I., & Apóstolo, J. (2021) · The Clinical Neuropsychologist · doi:10.1080/13854046.2021.1871962 · Cited by 51
Glial TDP‐43 and TDP‐43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes
Prater, K. E., Latimer, C. S., & Jayadev, S. (2021) · Glia · doi:10.1002/glia.24096 · Cited by 51
Lista, S., Vergallo, A., Teipel, S. J., Lemercier, P., Giorgi, F. S., Gabelle, A., Garaci, F., Mercuri, N. B., Babiloni, C., Gaire, B. P., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101819 · Cited by 50
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration
Kellett, E. A., Bademosi, A. T., & Walker, A. K. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00839-8 · Cited by 49
What have we learned from cognition in the oldest-old
Kawas, C. H., Legdeur, N., & Corrada, M. M. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000910 · Cited by 49
Self-citationLee, J. Y., Harney, D., Teo, J. D., Kwok, J. B., Sutherland, G. T., Larance, M., & Don, A. S. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00650-3 · Cited by 49
Walker, J. M., Orr, M. E., Orr, T. C., Thorn, E. L., Christie, T. D., Yokoda, R. T., Vij, M., Ehrenberg, A. J., Marx, G. A., McKenzie, A. T., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13484 · Cited by 48
TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43
Rummens, J., Khalil, B., Yıldırım, G., Silva, P., Zorzini, V., Peredo, N., Wojno, M., Ramakers, M., Bosch, L. V. D., Damme, P. V., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.03.004 · Cited by 48
Feneberg, E., Gordon, D., Thompson, A. G., Finelli, M. J., Dafinca, R., Candalija, A., Charles, P. D., Mäger, I., Wood, M. J. A., Fischer, R., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105050 · Cited by 48
Advances in Brain Amyloid Imaging
Krishnadas, N., Villemagne, V. L., Doré, V., & Rowe, C. C. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.005 · Cited by 47
Cykowski, M. D., Arumanayagam, A. S., Powell, S. Z.-E., Rivera, A. L., Abner, E. L., Román, G. C., Masdeu, J. C., & Nelson, P. T. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02416-5 · Cited by 48
Self-citationSerrano, G. E., Walker, J. E., Tremblay, C., Piras, I. S., Huentelman, M. J., Belden, C. M., Goldfarb, D., Shprecher, D., Atri, A., Adler, C. H., et al. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac056 · Cited by 48
Self-citationNeocortical Lewy Body Pathology Parallels Parkinson's Dementia, but Not Always
Martin, W. R. W., Younce, J. R., Campbell, M. C., Racette, B. A., Norris, S. A., Ushe, M., Criswell, S. R., Davis, A. A., Alfradique‐Dunham, I., Maiti, B., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26542 · Cited by 48
Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology
Yang, H.-S., White, C. C., Klein, H.-U., Yu, L., Gaiteri, C., Ma, Y., Felsky, D., Mostafavi, S., Petyuk, V. A., Sperling, R. A., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.05.010 · Cited by 47
Self-citationHoward, E., Irwin, D. J., Rascovsky, K., Nevler, N., Shellikeri, S., Tropea, T. F., Spindler, M., Deik, A., Chen-Plotkin, A., Siderowf, A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011699 · Cited by 47
Self-citationSamudra, N. P., Fischer, D. L., Lenio, S., Lago, A. L., Ljubenkov, P. A., Rojas, J. C., Seeley, W. W., Spina, S., Staffaroni, A. M., Tablante, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13799 · Cited by 48
Self-citationCurrent concepts and molecular pathology of neurodegenerative diseases
Forrest, S. L., & Kovács, G. G. (2024) · Pathology · doi:10.1016/j.pathol.2024.10.006 · Cited by 47
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function
Jiao, H.-S., Yuan, P., & Yu, J.-T. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00644-1 · Cited by 46
“LATE patients present an amnestic dementia syndrome that resembles AD [19], and autopsy studies have revealed that LATE patients show prevalent TDP-43 pro-teinopathy, some with concurrent hippocampal sclerosis.”
BackgroundBouvier, D. S., Fixemer, S., Heurtaux, T., Jeannelle, F., Frauenknecht, K. B. M., & Mittelbronn, M. G. A. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.814889 · Cited by 47
Cognitive Decline in Alzheimer’s Disease
Testo, A. A., Roundy, G., & Dumas, J. A. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_527 · Cited by 47
Hervás, R., & Oroz, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239186 · Cited by 46
Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions
Wisse, L. E. M., Ravikumar, S., Ittyerah, R., Lim, S., Lane, J., Bedard, M. L., Xie, L., Das, S. R., Schuck, T., Grossman, M., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01225-3 · Cited by 46
Self-citationMental Health of Older Adults: A Global Perspective of Inequalities and Inadequacies
Baiyewu, O., Esan, O., & Elugbadebo, O. O. (2021) · Springer eBooks · doi:10.1007/978-3-030-57296-9_119 · Cited by 46
Duong, M. T., Das, S. R., Lyu, X., Xie, L., Richardson, H., Xie, S. X., Yushkevich, P. A., (ADNI), A. D. N. I., Weiner, M., Aisen, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28941-1 · Cited by 44
Self-citationFrançois‐Moutal, L., Scott, D. D., Ambrose, A. J., Zerio, C. J., Rodriguez-Sanchez, M., Dissanayake, K., May, D. G., Carlson, J. M., Barbieri, E. M., Moutal, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12191-8 · Cited by 46
Katsumata, Y., Shade, L. M., Hohman, T. J., Schneider, J. A., Bennett, D. A., Farfel, J. M., Kukull, W. A., Fardo, D. W., & Nelson, P. T. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105880 · Cited by 47
Self-citationOpinion: more mouse models and more translation needed for ALS
Fisher, E., Greensmith, L., Malaspina, A., Fratta, P., Hanna, M. G., Schiavo, G., Isaacs, A. M., Orrell, R. W., Cunningham, T. J., & Acevedo‐Arozena, A. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00619-2 · Cited by 45
Nelson, R. S., Abner, E. L., Jicha, G. A., Schmitt, F. A., Di, J., Wilcock, D. M., Barber, J. M., Eldik, L. J. V., Katsumata, Y., Fardo, D. W., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01576-z · Cited by 45
Self-citationArnold, F. J., Cui, Y., Michels, S., Colwin, M. R., Stockford, C. M., Ye, W., Bharathi, V., Jansen‐West, K. R., Philippe, J., Gulia, R., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci182088 · Cited by 45
Self-citationGenetic networks in Parkinson’s and Alzheimer’s disease
Kelly, J., Moyeed, R. A., Carroll, C., Luo, S., & Li, X. (2020) · Aging · doi:10.18632/aging.102943 · Cited by 45
Altered thyroid hormone profile in patients with Alzheimer’s disease
Quinlan, P. S., Horváth, A., Eckerström, C., Wallin, A., & Svensson, J. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104844 · Cited by 45
Diagnostic test accuracy of telehealth assessment for dementia and mild cognitive impairment
McCleery, J. M., Laverty, J., & Quinn, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013786.pub2 · Cited by 45
Drake, J., Initiative, A. D. N., Chambers, A. B., Ott, B. R., & Daiello, L. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200759 · Cited by 45
Fani, L., Georgakis, M. K., Ikram, M. A., Ikram, M. K., Malik, R., & Dichgans, M. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01400-z · Cited by 47
Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy
Gauthreaux, K., Bonnett, T. A., Besser, L. M., Brenowitz, W. D., Teylan, M., Mock, C., Chen, Y.-C., Chan, K. C. G., Keene, C. D., Zhou, X.-H., et al. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa014 · Cited by 44
Self-citationGranulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology
de Majo, M., Koontz, M., Marsan, E., Salinas, N., Ramsey, A., Kuo, Y.-M., Seo, K., Li, H., Dräger, N., Leng, K., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.01.012 · Cited by 44
Diagnostic performance of plasma p‐tau217 and Aβ42/40 biomarkers in the outpatient memory clinic
Piura, Y. D., Figdore, D. J., Lachner, C., Bornhorst, J. A., Algeciras‐Schimnich, A., Graff‐Radford, N. R., & Day, G. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70316 · Cited by 44
The A/T/N model applied through imaging biomarkers in a memory clinic
Dodich, A., Mendes, A., Assal, F., Chicherio, C., Rakotomiaramanana, B., Andryszak, P., Festari, C., Ribaldi, F., Scheffler, M., Schibli, R., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04536-9 · Cited by 44
Rujeedawa, T., Félez, E. C., Clare, I. C. H., Fortea, J., Strydom, A., Rebillat, A., Coppus, A. M. W., Levin, J., & Zaman, S. H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194582 · Cited by 44
Disrupting pathologic phase transitions in neurodegeneration
Hurtle, B. T., Xie, L., & Donnelly, C. J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168549 · Cited by 43
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42
Gao, J., Wang, L., Gao, C., Arakawa, H., Perry, G. L., & Wang, X. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165580 · Cited by 42
TDP-43 Is Elevated in Plasma Neuronal-Derived Exosomes of Patients With Alzheimer’s Disease
Zhang, N., Gu, D., Meng, M., & Gordon, M. L. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00166 · Cited by 42
Phe-Gly motifs drive fibrillization of TDP-43’s prion-like domain condensates
Pantoja‐Uceda, D., Stuani, C., Laurents, D. V., McDermott, A. E., Buratti, E., & Mompeán, M. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001198 · Cited by 42
LATE-NC aggravates GVD-mediated necroptosis in Alzheimer’s disease
Koper, M. J., Tomé, S. O., Gawor, K., Belet, A., Schoor, E. V., Schaeverbeke, J. M., Vandenberghe, R. R., Vandenbulcke, M., Ghebremedhin, E., Otto, M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01432-6 · Cited by 42
The Vascular-Immune Hypothesis of Alzheimer’s Disease
Mehta, R. I., & Mehta, R. I. (2023) · Biomedicines · doi:10.3390/biomedicines11020408 · Cited by 37
Pagnotti, R. M. B., Pudumjee, S. B., Cross, C. L., & Miller, J. B. (2023) · Neurology · doi:10.1212/wnl.0000000000207159 · Cited by 42
Bermejo‐Pareja, F., & del Ser, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020536 · Cited by 42
Stress granule assemblyin vivois deficient in the CNS of mutant TDP-43 ALS mice
Dubinski, A. F., Gagné, M., Peyrard, S., Gordon, D., Talbot, K., & Velde, C. V. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac206 · Cited by 41
Pathology of neurodegenerative disease for the general neurologist
Cullinane, P. W., Wrigley, S., Parmera, J. B., Valério, F., Millner, T. O., Shaw, K., Pablo‐Fernández, E. D., Warner, T. T., & Jaunmuktane, Z. (2023) · Practical Neurology · doi:10.1136/pn-2023-003988 · Cited by 41
Emerging genetic complexity and rare genetic variants in neurodegenerative brain diseases
Perrone, F., Cacace, R., van der Zee, J., & Van Broeckhoven, C. (2021) · Genome Medicine · doi:10.1186/s13073-021-00878-y · Cited by 38
Anstey, K. J., Peters, R., Zheng, L., Barnes, D. E., Brayne, C., Brodaty, H., Chalmers, J., Clare, L., Dixon, R. A., Dodge, H., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200674 · Cited by 40
“This means that alternative methods, such as case-control studies, large-scale register-based studies, and data pooling, may be required to obtain better information on risk factors associated with dementias such as frontotemporal [42], Lewy body dementia [43], limbic-predominant age-related TDP-43 encephalopathy [44]…”
MethodSelf-citationIaccarino, L., Sala, A., Caminiti, S. P., Presotto, L., Perani, D., & Initiative, F. T. A. D. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190954 · Cited by 40
Agrawal, S., Farfel, J. M., Arfanakis, K., Al-Harthi, L., Shull, T., Teppen, T. L., Evia, A. M., Patel, M. B., Ely, E. W., Leurgans, S. E., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01493-7 · Cited by 40
“LATE-NC stages were classified into 4 stages based on previous studies [21, 22].”
MethodSelf-citationGil, R. S., Pascovici, D., Venturato, J., Brown-Wright, H., Mehta, P. M., Martin, L. M. S., Wu, J. X., Luan, W., Chui, Y. K., Bademosi, A. T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45646-9 · Cited by 40
In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use
López‐Carbonero, J. I., García-Toledo, I., Fernández-Hernández, L., Bascuñana, P., Moreno, M., Matías‐Guiu, J. A., & Corrochano, S. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00419-8 · Cited by 40
Metadata
- Authors
- Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., Coyle-Gilchrist, I. T. S., Chui, H. C., Fardo, D. W., Flanagan, M. E., Halliday, G., Hokkanen, S. R. K., Hunter, S., Jicha, G. A., Katsumata, Y., Kawas, C. H., Keene, C. D., Kovacs, G. G., Kukull, W. A., Levey, A. I., Makkinejad, N., Montine, T. J., Murayama, S., Murray, M. E., Nag, S., Rissman, R. A., Seeley, W. W., Sperling, R. A., White III, C. L., Yu, L., & Schneider, J. A.
- Affiliations
- University of Kentucky (US)
- Mayo Clinic in Florida (US)
- University of Pennsylvania (US)
- Mayo Clinic (US)
- Rush University Medical Center (US)
- Uppsala University (SE)
- Newcastle University (GB)
- University of Cambridge (GB)
- University of Southern California (US)
- University of Minnesota (US)
- The University of Sydney (AU)
- University of California, Irvine (US)
- University of Washington (US)
- Institute of Neurology Medical University of Vienna, Vienna, Austria
- Emory University (US)
- Illinois Institute of Technology (US)
- Stanford University (US)
- Tokyo Metropolitan Institute of Gerontology (JP)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Harvard University (US)
- University of Texas Southwestern Medical Center, Dallas, TX, USA
- Corresponding author
- Nelson, Peter T
- ORCID
- Nelson, Peter T
- Dickson, Dennis W
- Trojanowski, John Q
- Jack, Clifford R
- Boyle, Patricia A
- Arfanakis, Konstantinos
- Rademakers, Rosa
- Alafuzoff, Irina
- Attems, Johannes
- Brayne, Carol
- Coyle-Gilchrist, Ian T S
- Chui, Helena C
- Fardo, David W
- Flanagan, Margaret E
- Halliday, Glenda
- Hokkanen, Suvi R K
- Hunter, Sally
- Jicha, Gregory A
- Katsumata, Yuriko
- Kawas, Claudia H
- Keene, C Dirk
- Kukull, Walter A
- Levey, Allan I
- Makkinejad, Nazanin
- Montine, Thomas J
- Murayama, Shigeo
- Murray, Melissa E
- Nag, Sukriti
- Rissman, Robert A
- Seeley, William W
- Sperling, Reisa A
- Yu, Lei
- Schneider, Julie A
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-04-30
- Volume
- 142
- Issue
- 6
- Pages
- 1503-1527
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6536849
- OpenAlex
- W2943828894
- Cited by
- 1,547
- References
- 276
- Citations by year
- 2026: 206 · 2025: 240 · 2024: 211 · 2023: 214 · 2022: 213 · 2021: 193 · 2020: 198 · 2019: 66
- FWCI
- 113.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UKnowledge (University of Kentucky) (submittedVersion, cc-by-nc)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Apollo
- Funders
- NIA
- NACC
- NIH (U01 AG016976)
- National Health and Medical Research Council
- NHMRC (1132524, 1095127, 1037746)
- Senior Principal Research Fellowship (1079679)
- National Institutes of Health (P01 AG003949, R01 AG037491, P50 AG016574, R01 AG054449, P30 AG028303, P30 AG012300, P30 AG049638, P30 AG010124, P30 AG010161, P50 AG047366, P50 AG025688, P50 AG005131, R37 AG011378, R01 AG041851, R01 AG042210, R01 AG017917, R01 AG034374, UF1 AG053983, UF1 AG057707)
- NIHR (534906, NF-SI-0616–10090)
- National Institute for Health Research
- NHS
- Department of Health and Social Care
- Addenbrooke’s Charitable Trust
- Paul G. Allen Family Foundation and Alzheimer’s Research
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- limbic-predominant age-related TDP-43 encephalopathy, TDP-43 proteinopathy, hippocampal sclerosis, diagnostic criteria, neuropathological staging, amygdala, medial temporal lobe atrophy, genetic risk variants, gene regulatory networks, TMEM106B, ABCC9, apolipoprotein E, Alzheimer's disease, frontotemporal lobar degeneration
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Brain Diseases, Female, Humans, Male, Middle Aged, Retrospective Studies, Frontotemporal Lobar Degeneration, TDP-43 Proteinopathies, Frontotemporal Dementia, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.